BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9229320)

  • 1. The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
    Blijham GH
    J Infus Chemother; 1996; 6(3):114-7. PubMed ID: 9229320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
    J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
    Loeffler TM; Hausamen TU
    J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in development of chemotherapy of colorectal carcinoma].
    Köhne CH
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():33-7. PubMed ID: 8692117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
    Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
    Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
    Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
    Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
    Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose infusional 5-FU in the treatment of advanced colorectal cancer: a summary of the European experience.
    Wils JA
    J Infus Chemother; 1996; 6(3):145-8. PubMed ID: 9229327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
    Blijham G; Wagener T; Wils J; de Greve J; Buset M; Bleiberg H; Lacave A; Dalmark M; Selleslag J; Collette L; Sahmoud T
    J Clin Oncol; 1996 Aug; 14(8):2266-73. PubMed ID: 8708716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer.
    Stabuc B; Markovic A; Plesnicar A; Cizej TE
    Neoplasma; 2000; 47(4):248-52. PubMed ID: 11043831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
    Lutz MP; Wilke H; Wagener DJ; Vanhoefer U; Jeziorski K; Hegewisch-Becker S; Balleisen L; Joossens E; Jansen RL; Debois M; Bethe U; Praet M; Wils J; Van Cutsem E; ;
    J Clin Oncol; 2007 Jun; 25(18):2580-5. PubMed ID: 17577037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.
    Wilke H; Korn M; Vanhöfer U; Fink U; Stahl M; Preusser P; Köhne C; Klassen U; Harstrick A; Schmoll HJ; Seeber S
    J Infus Chemother; 1996; 6(3):123-6. PubMed ID: 9229322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.